The pharmaceutical industry is facing critical attention, particularly around drug pricing and development costs. Drug development cost is about 10% of the total healthcare spend in the United State. Broader issues such as local monopolies, utilization, unit, and costs and local monopolies, politics and a fragmented payer system contribute to the increasingly high costs to patient.

Challenging as these issues are, they must be addressed to lower patient costs. In this episode, our guests discuss more efficient drug development practices but also some of the broader issues within the United States healthcare system and the IRA’s impacts on not only US patients but the world.

Host

⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpace

Guests

⁠⁠Ali Pashazadeh⁠⁠, CEO,Treehill Partners

⁠⁠Dan Smithey⁠⁠, President, CEO and Co-founder, Serán BioScience

⁠⁠Matthew Price⁠⁠, COO and Co-founder, Promontory Therapeutics

⁠⁠Peter Rubin⁠⁠, Executive Director, No Patient Left Behind

⁠⁠Rob Williamson⁠⁠, President and COO, Triumvira Immunologics

Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of Helping Patients?

BioSpace

Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of Helping Patients?